NASDAQ:GOSS Gossamer Bio Q4 2024 Earnings Report $11.51 +0.52 (+4.77%) As of 09:59 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Gossamer Bio EPS ResultsActual EPS-$12.00Consensus EPS -$12.00Beat/MissMet ExpectationsOne Year Ago EPSN/AGossamer Bio Revenue ResultsActual Revenue$9.38 millionExpected Revenue$7.02 millionBeat/MissBeat by +$2.36 millionYoY Revenue GrowthN/AGossamer Bio Announcement DetailsQuarterQ4 2024Date3/18/2025TimeBefore Market OpensConference Call DateThursday, March 13, 2025Conference Call Time10:30AM ETUpcoming EarningsGossamer Bio's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual Report(10-K) Gossamer Bio Earnings HeadlinesGossamer Bio, Inc. Submits New Drug Application to U.S. Fda for Seralutinib for Treatment of Pulmonary Arterial HypertensionSeptember 24 at 1:04 AM | marketscreener.comMGossamer Bio, Inc. reicht bei der US-FDA einen Zulassungsantrag für Seralutinib zur Behandlung von pulmonaler arterieller Hypertonie einSeptember 24 at 1:04 AM | de.marketscreener.comDCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 24 at 1:00 AM | Paradigm Press (Ad)Gossamer Bio Files New Drug Application for SeralutinibSeptember 24 at 1:04 AM | finance.yahoo.comGossamer Bio Files First NDA for Seralutinib PAH DrugSeptember 23 at 4:50 PM | tipranks.comGossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial HypertensionSeptember 23 at 4:01 PM | businesswire.comSee More Gossamer Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email. Email Address About Gossamer BioGossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions. Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling. The company is evaluating seralutinib in clinical studies as a potential treatment for pulmonary arterial hypertension and related cardiopulmonary disorders. Founded in 2015 and headquartered in San Diego, California, Gossamer Bio operates primarily through research, clinical development and collaborations with biotechnology and pharmaceutical partners. Its programs are intended for patients in the United States and international markets, subject to clinical and regulatory review.View Gossamer Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
